Novavax (NASDAQ:NVAX) is on the verge of a probable FDA approval of its vaccine to prevent RSV (respiratory syncytial virus) infection in older adults. The company has said that results of its Phase 3 clinical trial named Resolve will be announced by the end of this quarter, which ends September 30th.
The Prevalence and Impacts of RSV
There is currently no vaccine for RSV. As the CDC's website explains, RSV...
David S. Brown Enterprises has bolstered its Retail Leasing team with the recent hiring of Michael Gosnell
The Virginia law firm Gentry Locke is pleased to announce the promotion of Scott A. Stephenson to
Pessin Katz Law is pleased to announce that Attorney Adam E. Konstas has been elected to Member
Skanska, a leading global construction and development firm, announces that Gary Orton has joined the company as
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2026 citybuzz
